Skip to content
drillr.ai
Sign up

603127.SH

JOINN Laboratories (China) Co., Ltd.

SSE · Healthcare · Medical - Diagnostics & Research · CN

Also listed · 06127.HK →
CNY 46.31
+6.31%
Ask drillr

  • Oct 29, 2026, 09:19 UTC

    Joinn Laboratories, Joinn Biologics and Sheng Tong Intelligence signed a strategic cooperation agreement with Jointown Pharmaceutical Group to collaborate on drug research and sales, early-stage project investment, AI healthcare and a biopharmaceutical industrial park.

    Source:

  • Oct 29, 2026, 08:26 UTC

    Jointown Pharmaceutical Group signed a three-year strategic cooperation agreement with WuXi AppTec, WuXi AppTec's subsidiary, and Sheng Tong Intelligence to cooperate in drug research and sales, early-stage investment, AI healthcare, and biopharmaceutical industrial parks.

    Source:

  • Oct 29, 2026, 04:33 UTC

    Beijing Zhaoyan Biotech Technology Co., Ltd. and Beijing Jitai Life Science Co., Ltd. jointly established Zhaotai Zhiyào (Beijing) Technology Co., Ltd., with registered capital of 54.31 million yuan.

    Source:

  • Oct 10, 2026, 06:48 UTC

    Joinn Laboratories and other shareholders established Zhāoyǎn Shēngtóng Intelligent Technology (Beijing) Co., Ltd., whose business scope includes AI hardware sales, AI software development, data processing and medical research.

    Source:

  • Sep 8, 2026, 13:51 UTC

    On September 8, 2026, Joinn Laboratories held its 2026 interim results briefing, reporting H1 2026 revenue of 704 million yuan (up 5.27% year-on-year) and net profit attributable to shareholders of 748 million yuan (up 1126.8% year-on-year), driven largely by a 735 million yuan fair value gain on biological assets, while its core laboratory services business remained loss-making.

    Source:

  • Aug 28, 2026, 08:55 UTC

    Joinn Laboratories released its 2026 interim report on August 28, reporting net profit attributable to shareholders of 748 million yuan, up 1126.8% year-on-year, and revenue of 704 million yuan, up 5.27% year-on-year.

    Source:

  • Jul 15, 2026, 01:50 UTC

    Joinn Laboratories (06127) issued a profit alert, expecting a significant increase in net profit for the first half of 2026 due to a rise in biological asset market prices.

    Source: